Phase 2 Depression and Anxiety Trial, Recruiting NCT07489651 Sponsor: Reunion Neuroscience Inc Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 2 Depression and Anxiety Trial, Recruiting

NCT07489651
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Generalized Anxiety Disorder according to standard diagnostic guidelines (called DSM-5-TR)
  • Women who are not currently pregnant and are not planning to become pregnant during the trial, and men who are not planning to cause a partner to become pregnant during the trial
  • People who are willing and able to follow the rules and requirements of the study throughout its duration

Who may not be able to join:

  • People who have a significant risk of suicide
  • People who have, or have previously had, bipolar disorder, schizophrenia, schizoaffective disorder, a psychotic disorder, or borderline personality disorder, or who have a parent or sibling with a history of psychosis or bipolar disorder
  • People who have another mental health condition that is considered their main or primary diagnosis
  • People who have other significant health conditions that would make participation in the study unsuitable (confirm with trial site)
  • People who have recently used, or who would need to use during the study, medications or therapies that are not permitted by the trial
  • People who have a known allergy, sensitivity, or intolerance to the study treatment or to any backup medications that may be used during the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mark Pollack, M.D., Reunion Neuroscience Inc

Phone: 1-888-880-REUN

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Reunion Neuroscience Inc
Registry
ClinicalTrials.gov
Start date
20 April 2026
Est. completion
1 February 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

RE104 30 mg versus placebo change from Baseline at Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov